© 2023 Cellaïon
Do you want to join our team?
you may apply for this position by sending your CV and
QA ANALYST – GcP
Cellaïon SA is currently hiring a QA Analyst – GcP.
– Writing of general quality system procedures to support business objectives and comply with regulatory requirements for clinical, production, logistics, QA and QC activities.
– Review and evaluate production batch and QC files (batch records, certificates of analysis and compliance, etc.) prior to the release of clinical batches.
– Manage and update quality assurance system documents.
More Info? Please, download the Job description!
A new article on the Multi-Target Effect of HALPCs in the NASH STAM model has recently been published in Cells Journal. “Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model”. Cells is an international, peer-reviewed, open access journal of cell biology, molecular biology, and biophysics This peer-reviewed publication recognizes HALPCs as part of the most recent advances in liver repair strategies. This article is the first to show the results of the in vitro and in vivo properties of HALPCs.
A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation
Phase I/II Trial of Liver–derived Mesenchymal Stem Cells in Pediatric Liver–based Metabolic Disorders
The new Walloon company Cellaïon makes its first closing.
Cellaion SA announces a total fundraising of EUR 23 million in 2022.
Cellaion SA announces the arrival of Walid Abi-Saab in its Board of Directors, the hiring of Griet Goddemaer to lead clinical development and the green light from the DSMB for the continuation of ACLF- Dheliver Clinical trial.